Guardant Health reported Q4 FY2025 total revenue of USD 281.3 million (+39%), driven by oncology revenue of USD 189.9 million (+30%) on about 79,000 oncology tests (+38%), screening revenue of USD 35.1 million on about 38,000 Shield screening tests (vs. 6,400 a year earlier), and biopharma & data revenue of USD 54.0 million (+9%). Q4 GAAP gross margin was 65% (vs. 62%), with non-GAAP gross margin at 66% (vs. 63%). Q4 net loss was USD 128.5 million, or USD 1.00 per share, and free cash flow was negative USD 54.2 million (vs. negative USD 83.4 million). For FY2025, Guardant Health posted total revenue of USD 982.0 million (+33%), including oncology revenue of USD 683.6 million (+26%) on about 276,000 tests (+34%), biopharma & data revenue of USD 210.1 million (+18%), and screening revenue of USD 79.7 million on about 87,000 Shield screening tests. FY2025 net loss was USD 416.3 million (USD 3.32 per share), and free cash flow was negative USD 233.1 million (vs. negative USD 274.9 million). Cash, cash equivalents, restricted cash and marketable debt securities totaled USD 1.3 billion at year-end. Recent updates included the first Guardant360 CDx companion diagnostic approval in colorectal cancer, an in-house Guardant360 CDx-based testing service launch in Italy, an expansion of Guardant Reveal to include late-stage therapy response monitoring (and a Reveal chemotherapy monitoring data package submitted to MolDx for Medicare reimbursement), a strategic collaboration with Merck around companion diagnostics using the Guardant Infinity Smart Platform, Shield CRC TRICARE coverage for eligible active-duty service members and families, and the acquisition of MetaSight Diagnostics for USD 59.0 million upfront cash plus up to USD 90.0 million in contingent consideration. Guardant Health guided FY2026 revenue of USD 1.25 billion to USD 1.28 billion (+27% to +30%), including screening revenue of USD 162 million to USD 174 million and screening volume of 210,000 to 225,000 tests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260219448137) on February 19, 2026, and is solely responsible for the information contained therein.